Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pembrolizumab monotherapy in advanced recurrent ovarian cancer
2015-003338-29Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in ovarian cancer, sponsored by Merck & Co. Primary endpoint: Overall response rate. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2015-003338-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003338-29.